FTC approves Valeant asset sales for Sanofi and Johnson & Johnson deals

With a 4-0 vote, the FTC has approved final consent orders remedying the anticompetitive effects of Valeant Pharmaceuticals’ proposed acquisitions of Sanofi and Johnson & Johnson’s dermatalogy businesses. For the Sanofi deal, Valeant has sold to Mylan Pharmaceuticals the manufacturing and marketing rights to products treating acne and actinic keratosis. For the Johnson & Johnson deal, Valeant has sold to Spear Pharmaceuticals the rights to an anti-wrinkle pharmaceutical product.

The orders settle charges of Section 7 Clayton Act and Section 5 FTC Act violations.

Source: FTC Press Release


Related content: Consumer Protection Economics at the FTC


More Articles